Immunotherapy of Hepatocellular Carcinoma
In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain
- PDF / 3,608,830 Bytes
- 170 Pages / 439.42 x 683.15 pts Page_size
- 98 Downloads / 223 Views
Immunotherapy of Hepatocellular Carcinoma
Immunotherapy of Hepatocellular Carcinoma
Tim F. Greten Editor
Immunotherapy of Hepatocellular Carcinoma
Editor Tim F. Greten Thoracic and Gastrointestinal Oncology Branch Center for Cancer Research, National Cancer Institute Bethesda, MD, USA
ISBN 978-3-319-64957-3 ISBN 978-3-319-64958-0 (eBook) DOI 10.1007/978-3-319-64958-0 Library of Congress Control Number: 2017953935 © Springer International Publishing AG 2017 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Printed on acid-free paper This Springer imprint is published by Springer Nature The registered company is Springer International Publishing AG The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland
Preface
Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical “inflammation-induced” cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer, as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell-based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing significant benefit to a minority of patients. In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview of fundamental immunological questions in liver cancer and tumorimmunology, which form the base fo
Data Loading...
